MarketCap
Facebook
X
Telegram
Humana Income Statement 2025-2006 | HUM
Brief overview of financial performance at Humana
This overview is based on financial performance over the past five years. Revenue reported by Humana was $77.2 billion at the beginning of the period and $130 billion at the end. Across the full period, sales moved by +68.1%; the average annual rate was 10.9%. The pace indicates confident and sustained business growth.
Over the period, EBITDA shifted from 5.5 billion dollars to 3.4 billion dollars, a change of −38.3%. EBITDA lagged revenue, showing weaker operating momentum. Comparing the endpoints gives EBITDA margins of 7.1% and 2.6%. Cost pressure reduced operating profitability.
The five-year change in net income was −64.7%: from $3.4 billion to $1.2 billion. Profit pressure may reflect higher operating, financing, or tax costs.
Over the period, capitalization shifted from 49.8 billion dollars to 23 billion dollars (−53.8%). The decline in value indicates softer investor confidence.
Summary assessment
The financial trajectory is weak and requires a cautious interpretation. The constructive conclusion rests on sales growth. The main areas of concern are pressure on operating profitability, a weaker final result and a narrow EBITDA buffer. Future reports should be judged by revenue momentum, margins, and the conversion of sales into net income.
Annual Income Statement Humana
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
23 B | 32.6 B | 45 B | 64.4 B | 55.8 B | 49.8 B | 46 B | 42.1 B | 40.8 B | 29.8 B | 24.3 B | 22.6 B | 15.5 B | 12 B | 14.6 B | 7.64 B | 5.38 B | 8.11 B | - | - |
Shares |
120 M | 121 M | 124 M | 126 M | 129 M | 132 M | 134 M | 137 M | 144 M | 149 M | 149 M | 154 M | 158 M | 161 M | 165 M | 168 M | 167 M | 167 M | - | - |
Historical Prices |
191 | 270 | 364 | 510 | 434 | 377 | 315 | 279 | 264 | 204 | 170 | 156 | 106 | 63.5 | 80 | 45.5 | 32.2 | 48.5 | 63 | 51.8 |
Net Income |
1.19 B | 1.21 B | 2.49 B | 2.81 B | 2.93 B | 3.37 B | 2.71 B | 1.68 B | 2.45 B | 614 M | 1.28 B | 1.15 B | 1.23 B | 1.22 B | 1.42 B | 1.1 B | 1.04 B | 647 M | 834 M | - |
Revenue |
130 B | 118 B | 106 B | 92.9 B | 83.1 B | 77.2 B | 64.9 B | 56.9 B | 53.8 B | 54.4 B | 54.3 B | 48.5 B | 41.3 B | 39.1 B | 36.8 B | 33.6 B | 30.7 B | 28.8 B | 25.3 B | - |
Operating Income |
2.7 B | 2.56 B | 4.01 B | 3.8 B | 3.15 B | 4.99 B | 3.19 B | 3.1 B | 4.26 B | 1.74 B | 2.35 B | 2.36 B | 2.06 B | 2.02 B | 2.34 B | 1.85 B | 1.71 B | 1.07 B | 1.36 B | - |
Interest Expense |
-451 M | -181 M | 493 M | 401 M | 326 M | 283 M | 242 M | 218 M | 242 M | 189 M | 186 M | 192 M | 140 M | 105 M | 109 M | 105 M | 106 M | 80.3 M | 68.9 M | - |
EBITDA |
3.4 B | 3.4 B | 4.79 B | 4.51 B | 3.74 B | 5.51 B | - | - | - | - | - | - | - | - | - | 2.12 B | 1.96 B | 1.29 B | 1.54 B | - |
Operating Expenses |
- | - | - | - | - | - | 61.7 B | 53.8 B | 49.5 B | 52.6 B | 51.9 B | 46.1 B | 39.3 B | 37.1 B | 34.5 B | - | - | - | - | - |
General and Administrative Expenses |
15.4 B | 13.7 B | 13.2 B | 12.7 B | 10.1 B | 10.1 B | 7.38 B | 7.52 B | 6.57 B | 7.28 B | 7.32 B | 7.64 B | 6.36 B | 5.83 B | 5.4 B | 4.38 B | 4.01 B | 3.74 B | 3.48 B | - |
All numbers in USD currency
Quarterly Income Statement Humana
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | 2010-Q3 | 2010-Q2 | 2010-Q1 | 2009-Q3 | 2009-Q2 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
120 M | 120 M | 121 M | 121 M | 120 M | 120 M | 121 M | 123 M | 125 M | 125 M | - | 127 M | 127 M | 127 M | - | 129 M | 129 M | 129 M | - | 132 M | 132 M | 132 M | - | 133 M | 135 M | 135 M | - | 138 M | 138 M | 138 M | - | 144 M | 145 M | 148 M | - | 149 M | 149 M | 149 M | - | 149 M | 149 M | 150 M | - | 155 M | 155 M | 155 M | - | 157 M | 158 M | 159 M | - | 161 M | 163 M | 164 M | - | 164 M | 167 M | 167 M | 168 M | 168 M | - | - | - |
Net Income |
1.19 B | 195 M | 545 M | 1.24 B | 480 M | 679 M | 741 M | 832 M | 959 M | 1.24 B | - | 1.2 B | 696 M | 930 M | - | 1.53 B | 588 M | 828 M | - | 1.34 B | 1.83 B | 473 M | 512 M | 689 M | 940 M | 566 M | 355 M | 644 M | 193 M | 491 M | 184 M | 499 M | 650 M | 1.12 B | -401 M | 450 M | 311 M | 254 M | 101 M | 314 M | 431 M | 430 M | 145 M | 290 M | 344 M | 368 M | -30 M | 368 M | 420 M | 473 M | 192 M | 426 M | 356 M | 248 M | 199 M | 445 M | 460 M | 315 M | 393 M | 340 M | 259 M | 302 M | 282 M |
Revenue |
39.6 B | 32.6 B | 32.4 B | 32.1 B | 29.4 B | 29.5 B | 29.6 B | 26.4 B | 26.7 B | 26.7 B | - | 22.8 B | 23.7 B | 24 B | - | 20.7 B | 20.6 B | 20.7 B | - | 20.1 B | 19.1 B | 18.9 B | 16.3 B | 16.2 B | 16.2 B | 16.1 B | 14.2 B | 14.2 B | 14.3 B | 14.1 B | 13.2 B | 13.2 B | 13.4 B | 13.7 B | 12.9 B | 13.6 B | 13.9 B | 13.7 B | 13.4 B | 13.2 B | 13.6 B | 13.7 B | 12.3 B | 12.1 B | 12.1 B | 11.6 B | 10.2 B | 10.2 B | 10.2 B | 10.4 B | 9.56 B | 9.56 B | 9.7 B | 10.2 B | 9.06 B | 9.3 B | 9.28 B | 9.19 B | 8.42 B | 8.65 B | 8.44 B | 7.72 B | 7.9 B |
Operating Income |
1.75 B | 400 M | 1.1 B | 2.01 B | 728 M | 1.14 B | 1.24 B | 1.21 B | 1.44 B | 1.72 B | - | 1.17 B | 1.22 B | 1.29 B | - | 628 M | 1.24 B | 1.22 B | - | 1.82 B | 2.44 B | 1.07 B | - | 868 M | 1.12 B | 847 M | - | 961 M | 862 M | 760 M | - | 858 M | 1.1 B | 1.74 B | - | 949 M | 683 M | 547 M | - | 695 M | 573 M | 790 M | - | 589 M | 681 M | 721 M | - | 621 M | 689 M | 765 M | - | 701 M | 590 M | 416 M | - | 726 M | 754 M | 524 M | 648 M | 562 M | 443 M | 496 M | 467 M |
Interest Expense |
34 M | -35 M | -200 M | -163 M | 92 M | -55 M | -63 M | 6 M | -54 M | 113 M | - | 102 M | 101 M | 90 M | - | 88 M | 79 M | 68 M | - | 75 M | 76 M | 60 M | - | 62 M | 60 M | 62 M | - | 53 M | 53 M | 53 M | - | 59 M | 58 M | 49 M | - | 47 M | 47 M | 47 M | - | 47 M | 47 M | 46 M | - | 38 M | 35 M | 35 M | - | 35 M | 35 M | 35 M | - | 26 M | 26 M | 26 M | - | 27 M | 28 M | 27 M | 26.1 M | 26.2 M | 26.3 M | 26.3 M | 26.6 M |
EBITDA |
1.92 B | 573 M | 1.28 B | 2.2 B | 938 M | 1.35 B | 1.44 B | 1.41 B | 1.63 B | 1.9 B | - | 1.2 B | 1.23 B | 1.47 B | - | 1.1 B | 1.25 B | 1.38 B | - | 2.21 B | 2.69 B | 1.2 B | - | 1.25 B | 1.36 B | 965 M | - | 1.29 B | 1.08 B | 869 M | - | 1.16 B | 1.3 B | 1.84 B | - | 1.24 B | 873 M | 641 M | - | 958 M | 751 M | 878 M | - | 829 M | 838 M | 800 M | - | 933 M | 895 M | 867 M | - | 939 M | 750 M | 494 M | - | 951 M | 905 M | 600 M | 713 M | 631 M | 506 M | 558 M | 527 M |
General and Administrative Expenses |
4.02 B | 4.08 B | 3.55 B | 3.38 B | 3.34 B | 3.15 B | 3.04 B | 3.27 B | 3.11 B | 2.98 B | - | 3.06 B | 3.17 B | 2.89 B | - | 2.6 B | 2.12 B | 2.01 B | - | 2.51 B | 2.35 B | 2.12 B | - | 1.89 B | 1.7 B | 1.66 B | - | 1.9 B | 1.76 B | 1.75 B | - | 1.69 B | 1.45 B | 1.55 B | - | 1.74 B | 1.7 B | 1.73 B | - | 1.69 B | 1.82 B | 1.94 B | - | 1.9 B | 1.84 B | 1.78 B | - | 1.54 B | 1.46 B | 1.45 B | - | 1.41 B | 1.38 B | 1.38 B | - | 1.36 B | 1.19 B | 1.26 B | 1.07 B | 1.16 B | 1.13 B | 1.05 B | 1 B |
All numbers in USD currency
The income statement is one of the three key financial reports of a company Humana (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Reports on the profits and losses of other stocks in the Health care industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Triple-S Management Corporation
GTS
|
- | 0.28 % | $ 847 M |  USA |
 |
Magellan Health, Inc.
MGLN
|
- | -0.19 % | $ 2.49 B | USA |
 |
Anthem
ANTM
|
- | -2.32 % | $ 107 B | USA |
 |
NovoCure Limited
NVCR
|
$ 14.84 | -2.56 % | $ 1.65 B |  Jersey |
 |
Molina Healthcare
MOH
|
$ 195.62 | 0.47 % | $ 10.3 B | USA |
 |
Centene Corporation
CNC
|
$ 62.22 | 2.32 % | $ 30.7 B | USA |
 |
CVS Health Corporation
CVS
|
$ 104.43 | -0.65 % | $ 132 B | USA |
 |
Cigna Corporation
CI
|
$ 279.05 | -3.0 % | $ 73.5 B | USA |
 |
UnitedHealth Group Inc.
UNH
|
$ 414.4 | -1.68 % | $ 376 B | USA |